Mielóma multiplex: vizsgálatok itt: Franciaország
92 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Creteil Cedex, Marseille, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00 - 3. fázisTaking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Lille Cedex, Nantes, Nice, Pierre-Bénite, Poitiers, Toulouse, Vandoeuvre Les Nancy
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Lyon, Paris, Pessac, Villejuif
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 1. fázisTaking peopleA Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Where
- Angers, Creteil Cedex, Lille, Montpellier Cedex 5, Nantes, Paris, Poitiers, Villejuif
- Életkor
- 18 év and over
- People
- 317 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00 - 1/2. fázisTaking peopleA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Where
- Pierre-Bénite, Toulouse Cedex 9, Tours Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Argenteuil Cedex, Chambéry, Lyon, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Angers, Cannes Cedex, Lille Cedex, Lyon, Montpellier Cedex 5, Nantes, Paris, Paris Cedex 13, Pessac Cedex, Poitiers, Rouen Cedex, Saint-Cloud, Toulouse Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Creteil Cedex, Montpellier Cedex 5, Nantes, Pessac, Pierre-Bénite, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 4. fázisTaking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Lille Cedex, Nantes, Paris, Pierre-Bénite, Poitiers
- Életkor
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Creteil, Dijon, Lille, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Strasbourg, Strasbourg Cedex 2, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 1. fázisTaking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Nantes, Pierre-Bénite, Rennes, Toulouse
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Creteil, Lille, Nancy Cedex, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Toulouse Cedex 9, Tours
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 2. fázisTaking peopleA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Argenteuil, Bayonne, La Tronche, Le Mans, Nantes, Quimper
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07589634 - 3. fázisTaking peopleA Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Lille, Montpellier, Nantes, Paris, Pessac, Pierre-Bénite, Toulouse, Tours, Vandœuvre-lès-Nancy
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Clermont-Ferrand, Lille, Limoges, Lyon Cedex08, Nantes, Nîmes, Paris, Pessac, Strasbourg, Tours
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 1/2. fázisTaking peopleAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Where
- Lille, Nantes
- Életkor
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Bayonne, Marseille, Pierre-Bénite, Rouen Cedex, Toulouse Cedex 9, Tours, Villejuif
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Créteil Cedex, Lille Cedex, Nantes, Paris, Pierre-Bénite
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Nantes, Nice, Paris Cedex 12, Poitiers, Toulouse Cedex 9, Tours, Villejuif
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Montpellier Cedex 5, Nantes, Paris, Poitiers, Toulouse
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - 1/2. fázisTaking peopleA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Lille Cedex, Nantes, Poitiers
- Életkor
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00 - 1. fázisTaking peopleA Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Lille Cedex, Nantes, Poitiers, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00 - 3. fázisTaking peopleA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Lille, Nantes, Paris, Toulouse
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Nantes, Paris, Poitiers
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 3. fázisTaking peopleA Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Amiens Cedex 1, Lille, Montpellier Cedex 5, Nantes, Pessac, Pierre-Bénite, Poitiers, Toulouse Cedex 9, Tours, Villejuif
- Életkor
- 18 év and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00 · EU 2025-523815-12-00